The Experts below are selected from a list of 9657 Experts worldwide ranked by ideXlab platform

Cristiana M Nascimentocarvalho - One of the best experts on this subject based on the ideXlab platform.

Dafne C Andrade - One of the best experts on this subject based on the ideXlab platform.

Philip F. Wheat - One of the best experts on this subject based on the ideXlab platform.

  • In vitro activity of roxithromycin against Moraxella catarrhalis.
    Diagnostic Microbiology and Infectious Disease, 1992
    Co-Authors: Robert C. Spencer, Philip F. Wheat
    Abstract:

    Abstract The in vitro activity of roxithromycin was compared with that of the other antimicrobiol agents (erythromycin, tetracycline, ampicillin, and clotrimoxazole) against 188 distinct clinical isolates of Moraxella catarrhalis . Of these, 106 strains (66%) produced β-lactamase. The MIC 30 of roxithromycin was 0.25 μg/ml compared with values of 0.5, 1 >8, >8:0.4 μ g/ml for erythromycin, tetracycline, ampicillin, and sulfamethoxazole-trimethoprim, respectively. These results, allied with its improved pharmacokinetic properties, suggest that roxithromycin should be an effective treatment in children and adults for upper and lower respiratory tract infections caused by M. catarrhalis .

  • In vitro activity of roxithromycin against Moraxella catarrhalis.
    Diagnostic microbiology and infectious disease, 1992
    Co-Authors: Robert C. Spencer, Philip F. Wheat
    Abstract:

    The in vitro activity of roxithromycin was compared with that of the other antimicrobial agents (erythromycin, tetracycline, ampicillin, and cotrimoxazole) against 188 distinct clinical isolates of Moraxella catarrhalis. Of these, 106 strains (66%) produced beta-lactamase. The MIC90 of roxithromycin was 0.25 micrograms/ml compared with values of 0.5, 1, greater than 8, greater than 8:0.4 micrograms/ml for erythromycin, tetracycline, ampicillin, and sulfamethoxazole-trimethoprim, respectively. These results, allied with its improved pharmacokinetic properties, suggest that roxithromycin should be an effective treatment in children and adults for upper and lower respiratory tract infections caused by M. catarrhalis.

Iyer G Parameswaran - One of the best experts on this subject based on the ideXlab platform.

  • Moraxella catarrhalis a human respiratory tract pathogen
    Clinical Infectious Diseases, 2009
    Co-Authors: Ellie J C Goldstein, Timothy F. Murphy, Iyer G Parameswaran
    Abstract:

    : Moraxella catarrhalis is an exclusively human pathogen and is a common cause of otitis media in infants and children, causing 15%-20% of acute otitis media episodes. M. catarrhalis causes an estimated 2-4 million exacerbations of chronic obstructive pulmonary disease in adults annually in the United States. M. catarrhalis resembles commensal Neisseria species in culture and, thus, may be overlooked in samples from the human respiratory tract. The prevalence of colonization of the upper respiratory tract is high in infants and children but decreases substantially in adulthood. Most strains produce beta-lactamase and are thus resistant to ampicillin but susceptible to several classes of oral antimicrobial agents. Recent work has elucidated mechanisms of pathogenesis and focused on vaccine development to prevent otitis media in children and respiratory tract infections caused by M. catarrhalis in adults with chronic obstructive pulmonary disease.

Olli Ruuskanen - One of the best experts on this subject based on the ideXlab platform.